- Home
- Publications
- Publication Search
- Publication Details
Title
Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
Authors
Keywords
-
Journal
Clinical & Translational Oncology
Volume 14, Issue 3, Pages 163-168
Publisher
Springer Nature
Online
2012-03-13
DOI
10.1007/s12094-012-0779-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Assessment of Topoisomerase II α Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization
- (2011) Atocha Romero et al. AMERICAN JOURNAL OF PATHOLOGY
- Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial
- (2011) F. P. O’Malley et al. BREAST CANCER RESEARCH AND TREATMENT
- Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
- (2011) M. Martin et al. BREAST CANCER RESEARCH AND TREATMENT
- Multifactorial Approach to Predicting Resistance to Anthracyclines
- (2011) Christine Desmedt et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
- (2011) Angelo Di Leo et al. LANCET ONCOLOGY
- ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
- (2010) J. C. Brase et al. CLINICAL CANCER RESEARCH
- Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy
- (2010) Michael F. Press et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
- (2010) John MS Bartlett et al. LANCET ONCOLOGY
- Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study
- (2009) Laura G. Estevez et al. Clinical & Translational Oncology
- Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
- (2009) J. A. Sparano et al. CLINICAL CANCER RESEARCH
- Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy inHER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013
- (2009) Lyndsay N. Harris et al. JOURNAL OF CLINICAL ONCOLOGY
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
- (2009) F. P. O'Malley et al. JNCI-Journal of the National Cancer Institute
- Expression of Human DNA Topoisomerase II-α in Squamous Cell Carcinoma of the Larynx and Its Correlation With Clinicopathologic Variables
- (2008) Jacob Shvero et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer
- (2008) A. Rody et al. BREAST CANCER RESEARCH AND TREATMENT
- TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance
- (2008) Nathalie Wong et al. INTERNATIONAL JOURNAL OF CANCER
- Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
- (2008) John M.S. Bartlett et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
- (2007) Alessandra Gennari et al. JNCI-Journal of the National Cancer Institute
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search